肝细胞癌与肝内胆管癌患者对阿替利珠单抗/贝伐珠单抗耐药后的分子靶向治疗
该研究在单中心对阿替利珠单抗/贝伐珠单抗进展后的肝细胞癌(HCC)和肝内胆管癌(H-CCK)患者进行全基因组/外显子组和RNA测序,由分子肿瘤委员会匹配靶向治疗。19例可分析患者中14例(76%)存在可操作基因组改变,9/14例(45%)接受匹配靶向治疗,部分患者获得影像学缓解。结论认为该策略可行,可能对一小部分患者有用。
要点
- 对阿替利珠单抗/贝伐珠单抗耐药的HCC/H-CCK患者,全基因组/外显子组和RNA测序可行。
- 19例可分析患者中14例(76%)存在至少一个可操作基因组改变,9/14例(45%)接受匹配靶向治疗。
- 1例CDK4扩增的H-CCK患者接受哌柏西利治疗获得16个月部分影像学缓解。
核心结论
- 基于分子指导的靶向治疗在阿替利珠单抗/贝伐珠单抗进展后的HCC/H-CCK患者中可行,可能对一小部分患者有用。
研究设计与样本
- 单中心研究,纳入135例接受阿替利珠单抗/贝伐珠单抗治疗的HCC和H-CCK患者,其中20例进展后获得基因组分析,19例有可分析数据(16例HCC,4例H-CCK)。
- 对肿瘤冷冻样本进行全基因组/外显子组和RNA测序,由分子肿瘤委员会根据基因组改变匹配靶向治疗,评估影像学缓解和总生存。
主要发现
- 19例可分析患者中,70%为男性,中位年龄57岁,65%有转移性疾病,45%有血管侵犯。
- 14例(76%)存在至少一个可操作基因组改变,9/14例(45%)接受匹配靶向治疗。
- 1例CDK4扩增的H-CCK患者接受哌柏西利治疗,获得16个月部分影像学缓解。
- 1例HER2高表达且同源重组评分高的H-CCK患者接受曲妥珠单抗/奥拉帕利治疗,疾病稳定。
- 1例TSC2双等位基因失活的HCC患者接受依维莫司治疗,获得完全影像学缓解;其余6例接受治疗的患者(均为HCC)疾病进展,包括3例接受曲美替尼、2例接受依维莫司、1例接受奥拉帕利。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The "French Medicine Genomic program 2025" has been designed to give patients with cancers that are refractory to systemic treatments access to off-label therapies adapted to their specific genomic profile. Herein, we reported the results of this program in patients with advanced hepatocellular carcinoma (HCC) and hepato-cholangiocarcinoma (H-CCK). METHODS: In one center, all patients with HCC or H-CCK who progressed under atezolizumab/bevacizumab with available tumor frozen samples benefited from whole-genome/-exome and RNA sequencing. Targeted therapies were matched to genomic alterations following the recommendations of a molecular tumor board and radiological response and overall survival were assessed. RESULTS: Among 135 patients with HCC and H-CCK treated by atezolizumab/bevacizumab, 20 patients benefited from genomic analysis after progression (16 HCC; 4 H-CCK). Nineteen patients had analyzable data, 70% were male, median age was 57 years, 65% had metastatic disease and 45% had vascular invasion. Among these 19 patients, 14 patients (76%) harbored at least one actionable genomic alteration and 9/14 received an adapted targeted therapy (45%). One patient with H-CCK showing CDK4 amplification was treated with palbociclib and achieved a partial radiological response for 16 months. Another patient with H-CCK, high HER2 overexpression and a high homologous recombination score was treated with trastuzumab/olaparib and had stable disease. One patient with an HCC and bi-allelic inactivation of TSC2 achieved a complete radiological response under everolimus. The remaining six treated patients (all HCC) had progressive disease, including three patients treated with trametinib, two with everolimus and one with olaparib. CONCLUSION: Molecular-based guided therapy is feasible in patients with HCC/H-CCK progressing under atezolizumab/bevacizumab and may be useful in a small subset of patients. IMPACT AND IMPLICATIONS: The use of whole-genome/-exome and RNA sequencing in clinical practice has not been reported in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma. Herein, we performed a pilot study which suggested that whole-genome/-exome and RNA sequencing is feasible on tumor biopsies from patients refractory to atezolizumab/bevacizumab, with a small subset of patients exhibiting at least one actionable genomic alteration and receiving an adapted targeted therapy. This proof-of-concept study suggests that this clinical strategy could benefit a small subset of patients. Finally, validation of this approach will be required in a larger cohort of patients.
引用
- Limousin W, Laurent-Puig P, Ziol M, et al. Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab. J Hepatol. 2023. PMID: 37647991. doi:10.1016/j.jhep.2023.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。